Secretoneurin increases monolayer permeability in human coronary artery endothelial cells

Surgery

Volumn 140, Issue 2, 2006, Pages 243-251

  Yan, Shaoyu ^a   Wang, Xinwen ^a   Chai, Hong ^a   Wang, Hao ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; FLUORESCENT DYE; HYDROETHIDINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; OCCLUDIN; PROTEIN ZO1; SECRETONEURIN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUPEROXIDE;

ARTERY PERMEABILITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CAPILLARY PERMEABILITY; CELL CULTURE TECHNIQUES; CORONARY VESSELS; DEXTRANS; ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPEPTIDES; PLASMA SUBSTITUTES; RNA, MESSENGER; SECRETOGRANIN II; SUPEROXIDES;

EID: 33746826039     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.04.001     Document Type: Article

References (36)

1. Ross R., and Glomset J.A. Atherosclerosis and the arterial smooth muscle cell. proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180 (1973) 1332-1339
2. Anderson T.J. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 34 (1999) 631-638
3. Britten M.B., Zeiher A.M., and Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 245 (1999) 315-317
4. Nielsen L.B. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 123 (1996) 1-15
5. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15 (1995) 551-561
6. Harhaj N.S., and Antonetti D.A. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36 (2004) 1206-1237
7. Lee T.Y., and Gotlieb A.I. Microfilaments and microtubules maintain endothelial integrity. Microsc Res Tech 60 (2003) 115-127
8. Schneeberger E.E., and Lynch R.D. The tight junction. a multifunctional complex. Am J Physiol Cell Physiol 286 (2004) C1213-C1228
9. Matter K., and Balda M.S. Signalling to and from tight junctions. Nat Rev Mol Cell Biol 4 (2003) 225-236
10. Tsukita S., Furuse M., and Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 11 (1999) 628-633
11. Kirchmair R., Hogue-Angeletti R., Gutierrez J., Fischer-Colbrie R., and Winkler H. Secretoneurin-a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience 53 (1993) 359-365
12. Wiedermann C.J. Secretoneurin. a functional neuropeptide in health and disease. Peptides 21 (2000) 1289-1298
13. Fischer-Colbrie R., Kirchmair R., Kahler C.M., Wiedermann C.J., and Saria A. Secretoneurin. a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci 6 (2005) 373-385
14. Kahler C.M., Kirchmair R., Kaufmann G., et al. Inhibition of proliferation and stimulation of migration of endothelial cells by secretoneurin in vitro. Arterioscler Thromb Vasc Biol 17 (1997) 932-939
15. Coppinger J.A., Cagney G., Toomey S., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103 (2004) 2096-2104
16. Kahler C.M., Kaufmann G., Kahler S.T., and Wiedermann C.J. The neuropeptide secretoneurin stimulates adhesion of human monocytes to arterial and venous endothelial cells in vitro. Regul Pept 110 (2002) 65-73
17. Kirchmair R., Gander R., Egger M., Hanley A., Silver M., Ritsch A., et al. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 109 (2004) 777-783
18. Kahler C.M., Schratzberger P., and Wiedermann C.J. Response of vascular smooth muscle cells to the neuropeptide secretoneurin. A functional role for migration and proliferation in vitro. Arterioscler Thromb Vasc Biol 17 (1997) 2029-2035
19. Ischia R., Hobisch A., Bauer R., et al. Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab 85 (2000) 355-360
20. Kirchmair R., Egger M., Walter D.H., et al. Secretoneurin, an angiogenic neuropeptide, induces postnatal vasculogenesis. Circulation 110 (2004) 1121-1127
21. Yan S., Chai H., Wang H., et al. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 138 (2005) 464-473
22. Madara J.L. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 60 (1998) 143-159
23. Chen C., Lu X.H., Yan S., Chai H., and Yao Q. HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun 335 (2005) 874-882
24. Kong C., Gill B.M., Rahimpour R., et al. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunol 88 (1998) 91-98
25. Vorbrodt A.W., and Dobrogowska D.H. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers. electron microscopist's view. Brain Res Brain Res Rev 42 (2003) 221-242
26. Firth J.A. Endothelial barriers. from hypothetical pores to membrane proteins. J Anat 200 (2000) 541-548
27. Parinandi N.L., Kleinberg M.A., Usatyuk P.V., et al. Hyperoxia-induced NAD(P)H oxidase activation and regulation by MAP kinases in human lung endothelial cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L26-L38
28. Wojciak-Stothard B., Entwistle A., Garg R., and Ridley A.J. Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and Cdc42 in human endothelial cells. J Cell Physiol 176 (1998) 150-165
29. Nguyen D.A., and Neville M.C. Tight junction regulation in the mammary gland. J Mammary Gland Biol Neoplasia 3 (1998) 233-246
30. Wassmann S., Laufs U., Stamenkovic D., et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105 (2002) 2083-2091
31. Ferro T.J., Gertzberg N., Selden L., Neumann P., and Johnson A. Endothelial barrier dysfunction and p42 oxidation induced by TNF-alpha are mediated by nitric oxide. Am J Physiol 272 (1997) L979-L988
32. De Keulenaer G.W., Alexander R.W., Ushio-Fukai M., Ishizaka N., and Griendling K.K. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329 Pt 3 (1998) 653-657
33. Holland J.A., Meyer J.W., Chang M.M., O'Donnell R.W., Johnson D.K., and Ziegler L.M. Thrombin stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium 6 (1998) 113-121
34. Jornot L., and Junod A.F. Differential regulation of glutathione peroxidase by selenomethionine and hyperoxia in endothelial cells. Biochem J 306 Pt 2 (1995) 581-587
35. Bost F., Aouadi M., Caron L., and Binetruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie 87 (2005) 51-56
36. Hoefen R.J., and Berk B.C. The role of MAP kinases in endothelial activation. Vascul Pharmacol 38 (2002) 271-273